A Blinded Evaluation of the Effectiveness and Efficacy of the MyHealthyPregnancy Application Statistical 
Analysis Plan  
This study will evaluate the effectiveness and efficacy of the MyHealthyPregnancy App, an app designed 
to reduce preterm birth risk. This study will use observational cohort data collected at the University of 
Pi[INVESTIGATOR_892521] 2019 and Febru ary of 2022.  
July 18, 2022  
Emily Grayek, Baruch Fischhoff  
1. Description of the study   
 
MyHealthyPregnancy (MHP) was developed using decision science principles to help prevent  
preterm birth. An observational cohort trial was conducted at the University of Pi[INVESTIGATOR_892522] 2019 until February 2022. This trial compare s the 
effectiveness of MHP to usual care for pregnant people who delivered at the University of 
Pi[INVESTIGATOR_45589] (UPMC). Patients at UPMC were able to d ownload the MHP app 
after receiving a prescription for the app , as indicated by [CONTACT_892529] . Those who  were 
prescribed the app and downloaded it  were in the MHP cohort . Those who were prescribed the 
app and did not download it were in the usual care co hort . Prescriptions were offered to  
pregnant people by [CONTACT_892530] a n early  prenatal visit at UPMC.  
 
EHR data is available for both cohorts of patients. It is the source of all measures, unless 
otherwise noted.  
 
A linear  effects model will be used to evaluate effectiveness by [CONTACT_892531] , preventing preterm birth risk.  
 
For each dependent measure, these models will control for primary predictors, as identified in 
the research literature, that  are available in the EHR.  
 
A dose -response model will be used to  estimate the effects of continuous measures of non -
adherence (as opposed to dichotomous non-adherence, such as not initiating app use). 
Multiple measures of adherence will be analyzed , inclu ding measures of daily use, weekly  
use, time to initiation, and time from discontinuation to birth.  
 
1.1. Princip al research objectives  
 
1.1.1.   Primary objective  
To compare gestational weeks at birth , for the MyHealthy Pregnancy (MHP) cohort, 
defined as pregnant peo ple who download ed the MyHealthyPregnancy app , thereby  
[CONTACT_892532] , compared to the usual care  cohort , defined as pregnant 
people, who were invited to download  the app , but did not do so . Analyses  control for  
predictors of preterm birth.  
 
1.1.2.   Secondary objectives  
1. To compare preterm birth , defined as delivery before [ADDRESS_1250132] of each type of measure . 
 
 
1.2. Study  design including blinding  
 
Given  the nature of the observational study , patients and providers were not blinded to the 
treatment condition (MHP, usual care) .  
 
The primary statistician will remain blinded to the treatment and usual care cohorts w ith the 
exception of using 20% of the unblinded data to evaluate confounders of the outcomes, build a 
model for propensity score matching, and evaluate confounders of MHP app usage.  
 
1.3. Method of allocation of groups  
 
Participants seeking prenatal care at th e UPMC  were offe red a prescription to download the 
MyHealthyPregnancy app during an early prenatal visit. Participants were prescribed the app  by 
 
1 Gestational weight gain will be evaluated based on 2009  Institute of Medicine  guidelines  (11). Recommended 
gestational weight gain depends on pregravid BMI and  if it is a singleton or multiple pregnancy.  
their obstetrician  or the EHR system  and had the option of downloading the app and 
consenting to trial partici pation. We have no direct knowledge of how obstetricians decided 
whether to offer the prescription or  if there was encouragement to download the app in 
addition to the automated EHR prescription . Participants who downloaded the app will be 
categorized as t he MyHealth yPregnancy (MHP) cohort. Participants who did not download the 
app will be categorized as the usual care cohort.  
 
1.4. Data collection  
 
1.4.1.   Eligibility Screening  
Participants were included in the study if they  were offered a prescription for 
MyHealthyPregnancy , were at least [ADDRESS_1250133].  
 
1.5. Sample Size Justification  
 
Due to the observational nature of the study  and recruitmen t context , it was not possible to 
predetermine the sample size based on statistical power for estimat ing the primary and 
secondary outcomes. Instead, all participants who met the inclusion criteria between 
September 2019 and February 2022 were included . The final sample  has 12,344 deliveries , 
divided between the  MHP and usual care cohort s (with 7147 in one and 5197 in the other, with 
their identities currently blinded) . This represents about 12,287 different participants (we only 
have information about the percent of multiple deliveries for participants who downloaded the 
app, 0.464%). Given the sample sizes in the two cohort s, there is 80% power to detect an effect 
size of 0.[ADDRESS_1250134] 
deviation of 1 0 days  (1), the study has 80% power to  detect a 0. 51 day difference in gestational 
age at birth between the cohorts.  
 
1.6. Overview  of proposed analyses  
 
EG will analyze the primary, secondary, and exploratory outcomes for the trial data. LH will 
generate data and  run models  as needed so that EG remains blinded  to the identity  of each 
cohort  (see section 2.5 ).  
 
The primary analys es will be multiple linear regression  models estimat ing average treatment 
effects of  the MHP app. Secondarily, dose -response model s will be created for the primary and 
secondary outcomes in order to understand the moderating effects of app usage.  
 
The primary and secondary outcomes for the study will come from electronic health record 
(EHR) data for trial participants. Given the source  and the nature of care for women who 
deliver  in the UPMC system , few outcome data are missing data. As such, imputa tion will not 
be used to account for missing outcome data . Instead,  participants will be excluded from 
analyses , if their  outcome data  is missing for an outcome measure .  
 
As a sensitivity analysis, propensity score matching will be used to create similar cohorts of 
participants , exclud ing participants whose propensity scores are outside the overlap in the 
covariate distribution s for the covariates that predict downloading the MHP app  (see section 
3.1.5) . We will calculate average treatment effects for thes e matched subset s of participants. 
Inverse probability of treatment weighting will be used as an additional sensitivity analysis to 
account for the potential lack of overlap in covariate distributions between the study cohorts.  
 
2. Data analysis plan ‚Äì data description  
 
2.1. Recruitment and representativeness of recruited patients  
 
A flow diagram will describe the flow of participants from prescription of the MHP app into the 
MHP and usual care  cohorts. The final diagram will be similar to Figure [ADDRESS_1250135] desired effects . As such, this study 
investigates app usage as a mediator of the outcome , rather than comparing users who did and 
did not meet a predetermined dosage.  
 
We will assess the following aspects of usage : how soo n after receiving the prescription 
participants in itiated app use  (in days) ; how soon  they discontinued app use prior to de livery  (in 
days since initiation) ; the percent age of days they used it overall  (within the usage period) ; and 
the percent age of weeks they used it  at least once (within the usage period) . See Appendix A 
for details  on the se use metrics . 
 
2.4. Loss to follow -up and other missing data  
 
Given data -sharing constraints with UPMC, outcome data is available only for participants who 
delivered at UPMC hospi[INVESTIGATOR_600]. LH will  report how many people downloaded the app and did not 
deliver at UPMC . This will allow us to estimate  the percent age of participants lost due to 
delivering out of the system.  
 
For included participants, there is  a very little missing data for the primary measure 
(80/[ZIP_CODE] =0.06% ). We  will assume that such data is missing at random and exclude 
participants whose data is missing for a measure from analyses  involving that measure . There is 
no missing data for the secondary measures. The same practice will be followed for the 
exploratory outcomes . No imputation  will be done  for any outcome measures .  
Missing categorical values for baseline covariates (baseline disease information and 
demographics) will not be imputed , but  treated as an additional category. Continuous variables 
missing less than 5% of the data wi ll be imputed with the median value for that variable. Two 
continuous baseline covariates are missing more than 5% of data ADI_NATRANK 
(1330/[ZIP_CODE]=9.7%) and PREGRAVID_WEIGHT (1318/[ZIP_CODE]=9.6%).  For these two variables, 
                 L     ‚Äô               used to investigate if the data is missing completely at 
random (MCAR), missing at random (MAR), or missing not at random (MNAR)  on 20% of the 
unblinded data . If the data appears to be MCAR or MNAR, median imputation will be used. If the 
data is MAR, mult iple imputation will be used. If multiple imputation is needed, LH will generate 
data for the missing values so that EG remains blinded . For all missing data, we will conduct 
sensitivity analyses , repeating analyses  of primary and secondary outcomes  using imput ed 
values two standard deviations above and below the median. See Appendix A for the full list of 
collected baseline covariates . 
 
2.5. Development of outcome measurements  
 
EG will view 20% of unblinded data to determine wh ich potential confounders to include in the 
outcome model s, in the addition to those identified in advance , based on previous research. 
Section 3.1.[ADDRESS_1250136] deviation will be reported for the MHP and usual 
care cohorts. For binary variables, frequency and proportion will be reported.  
 
2.7. Exploratory metric  
 
As an exploratory metric, we may calculate the patient cooperativity index (PCI) (2), which 
                    q     y                   ‚Äú          y  ‚Äù  x                             
app. The PCI is an odds ratio, where participants with a higher PCI are more likely to use the 
app one day after using it the previous day. In equation 2, p fs is the probability that a 
participant uses the app the day after not using the app and p ss is the probability that a 
participant uses the app the day after using the app. These probabilities will be calculated for 
participants who initiate use of the app, from that time until their last use.  
 
(2) 
ùëÉùê∂ùêº = ùëùùëìùë†(1‚àí ùëùùëìùë†) ‚ÅÑ
ùëùùë†ùë†(1‚àí ùëùùë†ùë† ‚ÅÑ ) 
 
 
 
3. Data analysis plan ‚Äì inferential analysis  
 
3.1. Main analys es of treatment differences   
 
The main analysis compare s the mean gestational weeks at birth between the MHP and usual 
care  cohorts . An estimate of the average treatment  effect, 95% confidence interval, and effect 
size will be reported. EG will remain blind to the 80% of outcome data not used to set the terms 
of the analysis (Section 2.5) .   
 
The primary and secondary outcome s will be evaluated at the 5% significance level . No 
correction for chance will be used for the primary outcome , as there is only one test. For the 9 
secondary outcomes, we will report both  corrected and uncorrected p -value s, using the 
Bonferroni correction  to reduce risk of reporting a false positive result. As a sensitivity analysis, 
the Bonferroni corrected p -values for ten outcome values will be reported in the supplemental 
material of the report.  
 
All tests will include all participants with data on th e outcome measure  involved . 
 
3.1.1.   Analysis of primary outcomes  
The difference in gestational weeks at birth will be evaluated using a linear effects model 
accounting for confounders of preterm birth , as measured at baseline . We estimate that 
about 57 out of 12,344 deliveries are for a second pregnancy f or participants included in 
the sample given that 0.464% of participants who downloaded the app had two deliveries 
in the sample. We have included these women in the sample bec ause we cannot exclude 
similar women in the usual care cohort given limitations in our data. Likewise, we cannot 
account for random effects  of multiple deliveries  using a mixed effects model.  
 
Baseline study variables will be included as confounders in th e model if (a) the literature 
has identified the variable as a confounder of preterm birth risk  and (b) they might 
plausibly have                        ‚Äô                             . If, for a variable, the 
evidence on condition (a) is inconclusive and c ondition (b) is possible , we will examine the 
data and include  the variable  if it passes a 10% change -in-estimates threshold for the 
outcome or for the likelihood of downloading the app . The change -in-estimate will be 
calculated by [CONTACT_892533]. Only 
baseline variables will be  evaluated as potential confounders , as they could not have been 
affected by [CONTACT_892534].   
 
We will report the results of two models for each outcome, one using only confou nders 
identified in the literature and one adding confounders identified empi[INVESTIGATOR_3675]  (Appendix A). 
Including fewer confounders will reduce the likelihood that the average treatment effect 
applies only to an unrepresentative subset of the population. Includ ing additional 
confounders will reduce the likelihood of statistical bias in estimating  the average 
treatment effect.  
 
The dataset contains many kn own confounders of preterm birth that could be included in 
the model including : 
- Previous preterm birth  (3) 
- Race (3) 
- Low body -mass index  (3,4)    
- Insurance type  (5) 
- Area deprivation index  (6) 
- Multiple gestations  (3) 
- Previous spontaneous abortions  (7) 
- Hypertension  (3) 
- Diabetes  (3) 
- Tobacco use  (3) 
 
There are also many known predictors of preterm birth that are not in the EHRs, hence not 
available for this study . They  includ e educational attai nment , marital status, 
interpregnancy interval, relati ves who delivered preterm, and genetic predictors of 
preterm birth (3).  
 
Some co llected covariates are specific to this dataset. One is hospi[INVESTIGATOR_563845] , which may 
capture differences in resources, practices, and patient populations . The second is the 
date of the first visit recorded in Epic , which may capture factors like access to care  or 
social conditions (e.g., the pandemic) . We will  include hospi[INVESTIGATOR_892523] a variable in all 
models. We will  not include  date of first visit as  it might be correlated with ones that affect 
the effectiveness of the app over time.  
 
Residual plots will be used to evaluate the models for heteroskedasticity and the need for 
using robust standard errors , in order to allow for violations in the assumption that 
observations are independent and identically distributed (8).   
 
Differences between the cohorts will be described using adjusted mean differences and p-
values . Results will be considered significant at p<0.05.  
 
3.1.2.   Analysis of secondary outcomes  
Analytical procedures  for the secondary outcomes  will follow those  for the primary 
outcome . Each outcome will have its own appropriate confounders . As with the primary 
outcome, t hese confounders  will be based on previous research and specified a priori . As 
needed, they will be  supplemented by [CONTACT_62866][INVESTIGATOR_892524] 20% subset, including 
baseline covariates specified in Appendix B , with a 10% change -in-estimate  threshold for 
inclusion .  
 
These confounders from the literature are available : 
 
1. Preterm birth defined as delivery b efore 37 gestational weeks.  
a. Same confounders as the primary outcome  
2. Clinical diagnoses of depression.  
a. History of anxiety and depression (9)  
b. Smoking  (9) 
c. Past pregnancy complications or loss (9) 
Unavailable: Lack of partner or soci al support  or having a problematic 
relationship , a history of abuse or child abuse, having had an unplanned or 
unwanted pregnancy,  perceived stress, cognitive style (          ‚Äú pessimism, 
anger and rumination; a tendency to be nervous, worried or shy; low self-
esteem and low self -efficacy; and high levels of neuroticism or psychoticism ‚Äù) , 
and single marital status (9).  
3. Anxiety rates (using ICD10 codes ).  
a. Histo ry of anxiety and depression (9)  
b. Smoking (9) 
c. Past pregnancy c omplications or loss (9) 
Unavailable: Same as anxiety  (9).  
4. Referral to behavioral health  
a. No confounders identified  
5. Referral to social work  
a. No confounders identified  
6. Preeclampsia  
a. Prior pre -eclampsia  (10) 
b. Chronic h ypertension (10) 
c. Pre-gestational diabetes (10) 
d. BMI >30 (10) 
Unavailable: Antiphospholipid antibody syndrome (10).  
7. Sufficient gestational weight gain  
a. Pre-pregnancy BMI (11) 
b. Age (11) 
Unavailable: Family violence;  marital status; food insecurity; maternal 
pregravid metabolic status; hyperemesis gravidarium; anorexia; past bariatric 
surgery  (11). 
8. Number of prenatal appointments attended  
a. No confounders identified  
9. Percent of required prenatal appointments attended  
a. No confounders identified  
  
3.1.3.   Analysis of exploratory outcomes  
For the exploratory outcomes , we will report only descriptive statistics specified in section 
2.6.  
 
3.1.4.   Dose -response analysis  
A dose -response analysis will be used to test usage as a mediator of each outcome. 
Multiple measurements of usage were col lected and are listed in Appendix A. Metrics 
specified in section 2.3 will be created by [CONTACT_892535] a given day. Logging into the app  without activity  will not count as app usage 
because this information was not collected for the full study  period. A ctivity use is also 
more likely to be associated with engagement with the app than is  login alone . Daily usage  
and weekly usage will be the dependent variables for the dose -response models . As an 
exploratory analys is, the PCI may be analyzed as a dependent variable.  The dose -response 
relationship will be analyzed for the primary and secondary outcomes using a multiple 
linear  effects model and the confounder adjustment method  (12). The model for 
adherence will be created using 20% of the unblinded data. The dose -response effect s for 
the primary outcome wil l be reported in the manuscript. The dose -response effect for the 
secondary outcomes will be reported in the supplemental material.  
 
3.1.5.   Additional statistical considerations  
Method for handling confounding by [CONTACT_892536], there may be incomplete overlap in covariates between the 
MHP and usual care cohorts. To account for this  possibility , inverse probability of treatment 
weighting will be used. P ropensity score matching  of comparable sub groups  will also be used   
and reported as a sensitivity analysis  (13).  
Propensity score matching works by [CONTACT_892537] . Logistic regression will be used to generate prop ensity scores ; 
nearest -neighbor matching without replacement will be used for matching. Baseline 
confounders will be included in the propensity score model , if they a re related to  the likelihood 
of receiving treatment and the outcome. Date of first visit  will not be included in the model  (for 
reasons given in Section 3.1.1) . Participants without similar propensity scores, defined as greater 
than  a caliper width, will be excluded from this sensitivity analysis. The average treatment 
effect will be calculate d for the included subset of similar participants.  
Austin recommends a  ‚Äúcaliper  width ,‚Äù defined as the difference between two propensity 
scores,  as ‚Äú q       0.                                                         y      ‚Äù (14). To 
balance the internal and external validi ty of this sensitivity analysis, this caliper width will be 
used , unless it excludes more than 20% of the sample. I n that case , the caliper width will be 
increased until 80% of the participants are included. If this is adjustment is needed, the results 
using the smaller caliper width will be reported in the supplemental material. Following  Austin 
(2011 ), standardized differences, QQ -plots, box plots, cumulative distribution functions, and 
empi[INVESTIGATOR_892525]  (13).  
Time -effects  
For the primary models, we have chosen not to include  the first appointment date as it could 
capture factors that affect the effectiveness of the app. During the study time frame, many 
outside factors could have affected the outcomes, especially due to the COVID -[ADDRESS_1250137], the date of the 
parti      ‚Äô                                     .  
 
4. Software  
Data will be delivered to EG through a HIPAA -compliant password protected sharefile site. The data 
will be downloaded in a csv format and R will be used for data description and analysis.  
References  
1.  Jukic AM, Baird DD, Weinberg CR, McConnaughey DR, Wilcox AJ. Length of human pregnancy and 
contributors to its natural variation. Hum Reprod [Internet]. [ADDRESS_1250138] 1;28(10):2848 ‚Äì55. 
Available from: https://doi.org/10.1093/humrep/det297  
2.  Fellows K, Stoneking CJ, Ramanathan M. Bayesian population modeling of drug dosing 
adherence. J Pharmacokinet Pharmacodyn [Internet]. 2015 [cited 2019 Jul 12];42:515 ‚Äì25. 
Available from: https://link -springer -
com.pr oxy.library.cmu.edu/content/pdf/10.1007%2Fs10928 -015-9439 -8.pdf  
3.  Goldenberg RL, Culhane JF, Iams JD, Romero R. Epi[INVESTIGATOR_264111]. Lancet 
[Internet]. 2008;371(9606):75 ‚Äì84. Available from: 
https://www.sciencedirect.com/science/artic le/pii/S0140673608600744  
4.  Hendler I, Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, et al. The Preterm 
Prediction study: Association between maternal body mass index and spontaneous and indicated 
preterm birth. Am J Obstet Gynecol [Internet]. 20 05 Mar 1;192(3):882 ‚Äì6. Available from: 
https://doi.org/10.1016/j.ajog.2004.09.[ADDRESS_1250139] -
A               A   I               : I                                    . W    ‚Äô  Heal 
Issues [Internet]. 2020;30(4):248 ‚Äì59. Available from: 
https://www.sciencedirect.com/science/article/pii/S1049386720300384  
6.  Valgimigli M, Garcia Garcia HM, Vrijens B, Vranckx P, McFadden EP, Costa F, et al. Standardized 
classification and framework  for reporting, interpreting, and analysing medication non -
adherence in cardiovascular clinical trials: a consensus report from the Non -adherence Academic 
Research Consortium (NARC). Eur Heart J [Internet]. 2018 Jul 9 [cited 2019 Jun 11]; Available 
from: h ttp://www.ncbi.nlm.nih.gov/pubmed/29992264  
7.  Jiang M, Mishu MM, Lu D, Yin X. A case control study of risk factors and neonatal outcomes of 
preterm birth. Taiwan J Obstet Gynecol [Internet]. 2018;57(6):814 ‚Äì8. Available from: 
https://www.sciencedirect.com/ science/article/pii/S1028455918302328  
8.  Mansournia MA, Nazemipour M, Naimi AI, Collins GS, Campbell MJ. Reflection on modern 
methods: demystifying robust standard errors for epi[INVESTIGATOR_187543]. Int J Epi[INVESTIGATOR_5541] [Internet]. 
2021 Feb 1;50(1):346 ‚Äì51. Available from: https://doi.org/10.1093/ije/dyaa260  
9.  Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety and 
depression: A systematic review. J Affect Disord [Internet]. 2016;191:62 ‚Äì77. Available from: 
https://www.science direct.com/science/article/pii/S0165032715302330  
10.  Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre -eclampsia determined in early 
pregnancy: systematic review and meta -analysis of large cohort studies. BMJ [Internet]. 2016 Apr 
19;35 3:i1753. Available from: http://www.bmj.com/content/353/bmj.i1753.abstract  
11.  Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines [Internet]. 
Washington, DC: The National Academies Press; 2009. Available from: 
https://nap.nati onalacademies.org/catalog/[ZIP_CODE]/weight -gain -during -pregnancy -reexamining -
the-guidelines  
12.  Mazza GL. Examining Dose -Response Effects in Randomized Experiments with Partial Adherence 
[Internet]. 2018. Available from: https://core.ac.uk/download/pdf/157755 537.pdf  
13.  Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding 
in Observational Studies. Multivariate Behav Res [Internet]. 2011/06/08. 2011 May;46(3):399 ‚Äì
424. Available from: https://pubmed.ncbi.nlm.nih.gov/218 [ZIP_CODE]  
14.  Austin PC. Optimal caliper widths for propensity -score matching when estimating differences in 
means and differences in proportions in observational studies. Pharm Stat [Internet]. 
2011;10(2):150 ‚Äì61. Available from: https://pubmed.ncbi.nlm.nih.g ov/20925139  
 
  
Appendix A  
Covariates and Outcomes  
Variable Name [CONTACT_892540]_ID  ID for each patient not related to patient information  ID 
MOM_AGE  Mother's age at time of delivery  Baseline covariate  
FINANCIAL_CLASS  Payor at time of delivery from Medipac (insurance level, 
might be like coverage) (i.e. name [CONTACT_806531] 'UPMC HEALTH 
NETWORK', 'MED PLUS', 'BEST HEALTH CARE', etc)  Baseline covariate  
HOSP_ROLLUP_GROUPI[INVESTIGATOR_1645]1  Payor at time of delivery from Medipac (i nsurance type) (i.e. 
specifies type of UPMC insurance, examples include 'UPMC 
Commercial', 'Other MA Managed', 'Other Commercial', etc)  Baseline covariate  
HOSP_ROLLUP_GROUPI[INVESTIGATOR_1645]2  Medicare, Medicaid, Self -pay, or Commercial Insurance  Baseline covariate  
HPFL AG Payor at time of delivery from Medipac (UPMC Health Plan 
Member flag, 1= has UPMC Health Plan, 0=Doesn't have it)  Baseline covariate  
PT_ZIP  Patient zipcode  Baseline covariate  
AD_ZIP_4  Patient zipcode, location extension (+4)  Baseline covariate  
ADI_NATRANK  Area deprivation index, national ranking ([ADDRESS_1250140] deprived)  Baseline covariate  
RACE  Race, as reported through UPMC  Baseline covariate  
MOM_HEIGHT  mother's height at time of delivery (cm)  Baseline covariate  
OB_GRAVIDITY  Number of pregnancies (includes current pregnancy, so if 
it's their first pregnancy, this will be a 1)  Baseline covariate  
OB_PARITY  Number of previous deliveries (will be 0 if it's their first 
pregnancy)  Baseline covariate  
OB_FULL _TERM  Number of previous full term pregnancies  Baseline covariate  
OB_PREMATURE  Number of previous premature deliveries (prior to 37 
gestational weeks)  Baseline covariate  
OB_ABORTIONS  Number of previous abortions, including 
theraputic/spontaneous abortions  Baseline covariate  
OB_LIVING  Number of previous live deliveries  Baseline covariate  
OB_SPONTANEOUS_AB  Number of previous miscarriage/spontaneous abortions  Baseline covariate  
OB_THERAPEUTIC_AB  Number of previous theraputic  abortions  Baseline covariate  
PREGRAVID_WEIGHT  mother's pre -pregnancy weight (kg)  Baseline covariate  
GESTAGE_ATVISIT_DAYS  This is the gestational age of the pregnancy at the time of 
prenatal visit. Calculated using the estimated delivery date 
((280 -(EPI[INVESTIGATOR_182051].OB_WRK_EDD_DT -pat_enc.contact_date)) 
). Baseline covariate  
PREGSTART_OBESE  Obese BMI at first prenatal visit (binary variable)  Baseline covariate  
PREGSTART_MORBIDOBESE  Morbidly obese BMI at first visit (binary variable)  Baseline covariate  
PREGSTART_HTN  Chronic hypertension at first prenatal visit (binary variable)  Baseline covariate  
PREGSTART_CKD  Chronic kidney disease at first prenatal visit (binary variable)  Baseline covariate  
PREGSTART_DIAB  Type I or Type II diabetes at first prenatal visit (binary 
variable)  Baseline covariate  
PREGSTART_ANXIETY  Diagnosed or active anxiety at first prenatal visit (binary 
variable)  Baseline covariate  
PREGSTART_DEPRESSION  Diagnosed or active depression at first prenatal visit (binary 
variable)  Baseline covariate  
PREGSTART_LIVER_DISEASE  Liver disease at first prenatal visit (binary variable)  Baseline covariate  
PREGSTART_TOBACCOUSE  Tobacco use history, recorded at first prenatal visit (options 
are "yes","never","quit","passive")  Baseline covariate  
PREGSTART_O_PREEXISTING
HTN  Pre-existing hypertension in any of these forms or 
combinations, complicating pregnancy: essential 
hypertension, hypertensive heart disease, hypertensive 
chronic kidney disease,  secondary hypertension, or 
unspecified hypertension. Diagnosed or listed as active 
problem at first prenatal visit. (binary variable); Definition 
came from EPIC codes  Baseline covariate  
PREGSTART_O_PREGINDUCE
DHTN_NOPROT  Gestational hypertension without s ignificant proteinuria, 
could occur during any trimester, childbirth, or puerperium. 
Diagnosed or listed as active problem at first prenatal visit 
(binary variable);  Baseline covariate  
PREGSTART_O_PREGINDUCE
D_PROTEDEMA_NOHTN  Gestational edema, gestationa l proteinuria, or gestational 
edema with proteinuria. Diagnosed or listed as active 
problem at first prenatal visit (binary variable);  Baseline covariate  
PREGSTART_O_PREECLAMPSI
A Preeclampsia diagnosed or listed as active problem at first 
prenatal visit (binary variable)  Baseline covariate  
PREGSTART_O_SUPERIMPOS
EDPREE  Preexisting hypertension with preeclampsia. Diagnosed or 
listed as active problem at first prenatal visit. (binar y 
variable); Definition came from EPIC codes  Baseline covariate  
PREGSTART_O_ECLAMPSIA  Eclampsia diagnosed or listed as active problem at first 
prenatal visit (binary variable)  Baseline covariate  
PREGSTART_O_UNSPHTN  Unspecified maternal hypertension. Diag nosed or listed as 
active problem at first prenatal visit. (binary variable);  Baseline covariate  
PREGSTART_O_ANYHTN  Pre-existing hypertension in any of these forms or 
combinations, complicating pregnancy: essential 
hypertension, hypertensive heart disease, hypertensive 
chronic kidney disease, secondary hypertension, or 
unspecified hypertension. Diagnosed or listed as ac tive 
problem at first prenatal visit. (binary variable);  Baseline covariate  
PREGSTART_O_CARDIOMYOP
ATHY  Disease of the circulatory system affecting any stage of 
pregnancy. Diagnosed or listed as active problem at first 
prenatal visit. (binary variable); D efinition came from EPIC 
codes  Baseline covariate  
PREGSTART_O_GDM  Gestational diabetes mellitus. Diagnosed or listed as active 
problem at first prenatal visit. (binary variable)  Baseline covariate  
PREGSTART_MEDREPORTED  Medications reported at first prena tal visit (binary variable)  Baseline covariate  
PREVIOUS_GDM  Previous GDM in a prior pregnancy, not including this 
current pregnancy (gestational diabetes) (binary variable)  Baseline covariate  
PREVIOUS_OBANYHTN  Previous gestational hypertension in a prior pregnancy, not 
including this current pregnancy (binary variable)  Baseline covariate  
PREVIOUS_PREECLAMPSIA  Previous preeclampsia in a prior pregnancy (binary variable)  Baseline covariate  
AUTOIMMDX_PT20WKS  Previous gestational auto immune disease prior to 20 weeks 
(in prior pregnancy) (binary variable)  Baseline covariate  
PRIOR_SBBTW16AND34  Prior stillborn between 16 and 34 weeks in a prior 
pregnancy (binary variable)  Baseline covariate  
PRIOR_LBBTW31AND36  Prior premature live birth between 31 and 36 weeks in a 
prior pregnancy (binary variable)  Baseline covariate  
PRIOR_SBAFTER34  Prior stillborn after 34 weeks in a prior pregnancy (binary 
variable)  Baseline covariate  
PRIOR_VPTBBTW222AND30  Prior very premature birth between 22 a nd 30 weeks in a 
prior pregnancy (binary variable)  Baseline covariate  
PRIOR_STILLBORN  Prior stillborn (time period not specified) in a prior 
pregnancy (binary variable)  Baseline covariate  
PRIOR_PPROM  Prior preterm premature rupture of membranes in a prio r 
pregnancy (binary variable)  Baseline covariate  
PRIOR_PPROMBEFORE37  Prior preterm premature rupture of membranes before 37 
weeks in a prior pregnancy (binary variable)  Baseline covariate  
HOSPI[INVESTIGATOR_892526]  1=singleton birth, 0=twins, triplets, etc (binary variable)  Baseline covariate  
PREG_CONTACT_DATE  First visit in Epic while pregnant  Baseline covariate  
EST_GEST_AGE_DAYS  gestational age at the time of birth  Primary outcome  
MOM_DELIVERY_WT  weight of mother at time of delivery (kg)  Secondary outcome  
PREGANY_DEPRESSION  Diagnosis of depression or active depression at some point 
during pregnancy (would also be 1 if 
PREGSTART_DEPRESSION is 1) (binary variable)  Secondary outcome  
PREGANY_ANXIETY  Diagnosis of anxiety or active anxiety at some point during 
pregnancy (would also be 1 if PREGSTART_ANXIETY is 1) 
(binary variable)  Secondary outcome  
PREGANY_PREE  Preeclampsia diagnosed or listed as active problem at any 
visit while pregna nt (binary variable)  Secondary outcome  
PNV_COUNT  Number of prenatal appointments attended  Secondary outcome  
PNV_TOTSCHED  Number of prenatal appointments scheduled (blank if the 
same as PNV_COUNT i.e. they didn't cancel any 
appointments)  Secondary outcome  
PREGANY_BEHAVIORALREF  Behavioral health referral at some point during pregnancy 
(binary variable)  Secondary outcome  
PREGANY_SWREF  Social work referral at some point during pregnancy (binary 
variable)  Secondary outcome  
BABY_DISPOSITION  baby's disposition after birth (home health agency, 
home/self care, children's hospi[INVESTIGATOR_307], cease to breathe, etc)  Exploratory outcome  
STILLBORN  whether this baby [CONTACT_892538] (binary variable)  Exploratory outcome  
C_SECTION  Had c -section ( binary variable)  Exploratory outcome  
BIRTH_WEIGHT  baby's birth weight in grams  Exploratory outcome  
NICU_DELIVERYADMISSION  whether the baby [CONTACT_892539] (binary variable)  Exploratory outcome  
ASSUMED_INDUCTION  If a delivery was by c -section prior to 259 days gestation, 
but there is no documentation of induction then we assume Exploratory outcome  
it was indicated and this column has a 1 (binary variable). 
Otherwise, it's 0. Definition came from Hy.  
INDICATED_ONS ET When a delivery form documents that a delivery was 
induced but not for PROM (binary variable). Definition came 
from Hy.  Exploratory outcome  
CURRENT_PPROM  premature rupture of membranes; diagnosis of O42* during 
current delivery (binary variable).  Explo ratory outcome  
VISITNUMBER_F2F  Number of face -to-face visits when pregnant.  Exploratory outcome  
PREGANY_PREGINDUCEDHTN
_NOPROT  Gestational hypertension without significant proteinuria, 
could occur during any trimester, childbirth, or puerperium; 
Diagnosed or listed as active problem at any visit while 
pregnant. Definition came from EPIC codes  Exploratory outcome  
PREGANY_SUPERIMPPREE  Superimposed Preeclampsia diagnosed or listed as active 
problem at any visit while pregnant (binary variable)  Exploratory outcome  
PREGANY_ECLAMPSIA  Eclampsia diagnosed or listed as active problem at any visit 
while pregnant (binary variable)  Exploratory outcome  
PREGANY_UNSPHTN  Unspecified hypertension diagnosed or listed as active 
problem at an y visit while pregnant (binary variable)  Exploratory outcome  
PREGANY_ANYHTN  Any hypertension diagnosed or listed as active problem at 
any visit while pregnant (binary variable)  Exploratory outcome  
PREGANY_GDM  Gestational diabetes diagnosed or listed as active problem 
at any visit while pregnant (binary variable)  Exploratory outcome  
CANCELEDVISIT_COUNT  Number of prenatal appointments canceled (blank if 0 
appointments canceled)  Exploratory outcome  
ANTEPARTUM_EDLD  Number of EDLD visits during pr egnancy (EDLD = Emergency 
Department Labor and Delivery)  Exploratory outcome  
ANTEPARTUM_EDTR  Number of ER visits during pregnancy  Exploratory outcome  
ANTEPARTUM_ADMISSION  N         ‚ÄòI ‚Äô    ‚ÄòO ‚Äô                                 y 
start date in Epic and delivery  Exploratory outcome  
ANTEPARTUM_LOS  Sum of all antepartum admission lengths of stays for each 
delivery.  Exploratory outcome  
POSTPARTUM_EDTR  Number of postpartum visits to ER up to 42 days after 
pregnancy  Exploratory outcome  
POSTPARTUM_ADMISSION  N         ‚ÄòI ‚Äô    ‚ÄòO ‚Äô                                y      
and 42 days postpartum.  Exploratory outcome  
POSTPARTUM_LOS  Sum of all postpartum admission between delivery date and 
42 days postpartum.  Exploratory outcome  
POSTPARTUM_NICU  Provided flags for infant ICU admission within 42 days 
postpartum.  Exploratory outcome  
PP_LOS  postpartum length of stay in hospi[INVESTIGATOR_892527] -in (includes responses to 
questions on daily mood, number of hours slept, sleep quality, SDOH 
questions, aspi[INVESTIGATOR_892528], etc)  
ArticleReads  Dates of clicking on any article within the app (only after November 
2020)  
MentalHealthCheckin  Dates of filling out  mental health check -in 
RelationshipHealthCheckin  Dates of filling out relationship health check -in 
SleepHealthCheckin  Dates of filling out sleep health check -in 
HelpfulResource  Dates of looking at the helpful resource section (only after November 
2020)  
HelpfulResourceClick  Dates of clicking on a helpful resource from the helpful resources 
section (only after November 2020)  
OpensApp  Dates of accessing the app at all (best after November 2020, but can 
also seem many things before November 2020)  
Kick Counter  Dates of logging a kick -counting session in Kick Counter section of the 
app 
Contraction Counter  Dates of logging contractions in the Contraction Counter section of 
the app  
Journaling Section (just dates)  Dates of entering a journal into the journaling section of the app  
Adding appointment reminders  Dates of adding in an appointment into the Prenatal Visits section of 
the app  
 
 
 